uniQure N.V. Ordinary Shares (QURE)
Stock · NASDAQ · Health Care
$21.78as of 10/16/2026
Price chart
Active signals
QURE Signal Track Record
How signals performed across all stocks →What QURE's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 34 | -1.5% | 44% | September 24, 2026 |
| Bollinger Band Breakout | 24 | +0.9% | 50% | August 7, 2026 |
| Bollinger Band Breakdown | 20 | -0.9% | 40% | September 24, 2026 |
| 200-Day Moving Average TouchActive now | 18 | +4.3% | 61% | June 16, 2026 |
| Any 20-session window (baseline) | -3.2% | 43% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About QURE
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develo…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 221
- Website
- www.uniqure.com/
Fundamentals
- 1-day range
- $23.69$24.9
- Market cap
- $3.15B
- P/E (trailing)
- —
- P/E (forward)
- -7.90
- EPS (trailing)
- $-4.05
- Dividend yield
- —
- Beta
- 1.07
- Avg. volume
- 1.91M
How uniQure N.V. Ordinary Shares Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 2, 2026 · via SEC EDGAR / Finnhub
Forecasts
11 analyst ratings
uniQure N.V. Ordinary Shares Competitors
Chosen by industry and closest market cap.
- QUREuniQure N.V. Ordinary Shares$21.78▼ 3.29%Market cap $3.15BP/E —$8.73$71.5
- MBXMBX Biosciences Inc. Common Stock$49.61▼ 2.17%Market cap $3.19BP/E —$12.94$72.64
- NAMSNewAmsterdam Pharma Company N.V. Ordinary Shares$19.83▼ 3.83%Market cap $3.23BP/E —$20.91$42.21
- ARQTArcutis Biotherapeutics Inc. Common Stock$28.82▼ 0.96%Market cap $3.31BP/E 128.52$19.3$31.77
- IRONDisc Medicine Inc. Common Stock$56.84▲ 0.34%Market cap $2.97BP/E —$40$99.5
- IMNMImmunome Inc. Common Stock$16.47▼ 5.34%Market cap $2.92BP/E —$13.54$30.06
- IDYAIDEAYA Biosciences Inc. Common Stock$32.85▼ 2.95%Market cap $3.50BP/E —$26.44$42.68
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| QURE uniQure N.V. Ordinary Shares | $3.15B | — | $21.78 | ▼ 3.29% | $8.73$71.5 |
| MBX MBX Biosciences Inc. Common Stock | $3.19B | — | $49.61 | ▼ 2.17% | $12.94$72.64 |
| NAMS NewAmsterdam Pharma Company N.V. Ordinary Shares | $3.23B | — | $19.83 | ▼ 3.83% | $20.91$42.21 |
| ARQT Arcutis Biotherapeutics Inc. Common Stock | $3.31B | 128.52 | $28.82 | ▼ 0.96% | $19.3$31.77 |
| IRON Disc Medicine Inc. Common Stock | $2.97B | — | $56.84 | ▲ 0.34% | $40$99.5 |
| IMNM Immunome Inc. Common Stock | $2.92B | — | $16.47 | ▼ 5.34% | $13.54$30.06 |
| IDYA IDEAYA Biosciences Inc. Common Stock | $3.50B | — | $32.85 | ▼ 2.95% | $26.44$42.68 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Micron, Nike To Headline Earnings Next Week; GDP Numbers AwaitedSeekingAlpha · 9/26/2026
Insider Activity
Insider Actions →- Kapusta Matthew C · July 2, 2026 · Option Exercise21.1K @ $19.39
- Kapusta Matthew C · July 2, 2026 · Sale7.6K @ $45.89
- Kapusta Matthew C · July 2, 2026 · Sale4.3K @ $45.43
- Kapusta Matthew C · July 2, 2026 · Sale9.2K @ $44.43
- Abi-Saab Walid · June 30, 2026 · Option Exercise10.0K @ $5.59
- Abi-Saab Walid · June 30, 2026 · Sale20.0K @ $46.4
- Abi-Saab Walid · June 30, 2026 · Sale10.0K @ $46.46
- Jack Kaye · June 30, 2026 · Option Exercise17.1K @ $20.18
- Jack Kaye · June 30, 2026 · Option Exercise4.1K @ $37
- Jack Kaye · June 30, 2026 · Sale17.1K @ $46.43
- Jack Kaye · June 30, 2026 · Sale4.1K @ $46.49
- Kapusta Matthew C · June 25, 2026 · Option Exercise28.7K @ $31.71
- Kapusta Matthew C · June 25, 2026 · Sale28.7K @ $50.02
- Kapusta Matthew C · June 24, 2026 · Option Exercise4.1K @ $31.71
- Kapusta Matthew C · June 24, 2026 · Sale6.7K @ $50
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
QURE shares fall after Huntington data update and Barclays downgrade
Cedar Grove Capital released its Q3 2026 portfolio update, noting QURE holdings. The stock fell 5.9% after Huntington's gene therapy data was updated, prompting a Barclays downgrade to equal‑weight and a new price target of $28. The move comes amid a broader market pullback, with the shares near a 17.1 RSI and a support level of $44.06.
QURE shares fall after Huntington data update and Barclays downgrade. Cedar Grove Capital released its Q3 2026 portfolio update, noting QURE holdings. The stock fell 5.9% after Huntington's gene therapy data was updated, prompting a Barclays downgrade to equal‑weight and a new price target of $28. The move comes amid a broader market pullback, with the shares near a 17.1 RSI and a support level of $44.06.